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Background. Laparoscopic adjustable gastric banding (LAGB) results in significant lasting weight loss and improved metabolism in
obese patients. To evaluate whether epigenetic factors could concur to these benefits, we investigated the subcutaneous adipose
tissue (SAT) microRNA (miRNA) profile before (T0) and three years (T1) after LAGB in three morbidly obese women. Case
Reports. SAT miRNA profiling, evaluated by TaqMan Array, showed four downexpressed (miR-519d, miR-299-5p, miR-212, and
miR-671-3p) and two upexpressed (miR-370 and miR-487a) miRNAs at T1 versus T0. Bioinformatics predicted that these miRNAs
regulate genes belonging to pathways associated with the cytoskeleton, inflammation, and metabolism. Western blot analysis
showed that PPAR-alpha, which is the target gene of miR-519d, increased after LAGB, thereby suggesting an improvement in
SAT lipid metabolism. Accordingly, the number and diameter of adipocytes were significantly higher and lower, respectively, at
T1 versus T0. Bioinformatics predicted that the decreased levels of miR-212, miR-299-5p, and miR-671-3p at T1 concur in reducing
SAT inflammation. Conclusion. We show that the miRNA profile changes after LAGB. This finding, although obtained in only
three cases, suggests that this epigenetic mechanism, by regulating the expression of genes involved in inflammation and lipid
metabolism, could concur to improve SAT functionality in postoperative obese patients.
1. Introduction
Obesity is a major health problem worldwide [1]. Besides
lifestyle interventions and pharmacotherapy, significant, last-
ing weight loss in obese patients can be obtained with
laparoscopic adjustable gastric binding (LAGB) surgery [2, 3].
This procedure is usually applied in morbidly obese patients
(BMI greater than 40 kg/m2) and/or if obesity is associated
with comorbidities, such as diabetes or cardiovascular dis-
eases [4]. We previously reported that LAGB also improved
metabolism, in terms of inflammation, insulin resistance,
and liver steatosis, three years after LAGB [3]. MicroRNAs
(miRNAs) are short (19–22 bp) noncodingRNAs that regulate
the expression ofmRNA targetsmainly by binding their com-
plementary sequences at the 3󸀠 untranslated region (3󸀠UTR)
and inhibiting their translation [5]. The miRNA profile in
subcutaneous (SAT) and in visceral (VAT) adipose tissues
differs between obese and lean subjects [6, 7]. The aim of the
present study was to investigate the SAT miRNA profile in
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threemorbidly obese women before (T0) and three years (T1)
after LAGB and to evaluate whether miRNAs are involved in
post-LAGB metabolic improvement.
2. Methods
2.1. Patients. Three obese women (mean body mass index
[BMI] 42.9 kg/m2; mean age 48 years) undergoing LAGB (at
T0 and T1) and two lean controls (mean BMI 21.5 kg/m2;
mean age 37 years) undergoing laparoscopic cholecystectomy
entered the study. All subjects gave informed consent to the
study, which was performed according to the Helsinki II
Declaration and was approved by the Ethics Committee of
our School of Medicine.
2.2. Serum Determinations. A fasted serum sample was
also collected from enrolled subjects, the main biochemical
parameters were measured by routine methods; leptin (L)
and adiponectin (A) adipokines were measured by ELISA
methods and the L/A ratio was calculated.
2.3. Adipocytes Size and Number Quantification. Periumbil-
ical bioptic SAT samples were obtained from all subjects.
All biopsies were snap-frozen and stored in liquid nitrogen
until RNA isolation.The number and diameter of adipocytes
(at T0 and T1) were measured as previously reported [3].
Briefly, hematoxylin and eosin stains were used to identify the
cellular components and their morphological changes. For
each sample, adipocytes were counted in three fields (100 𝜇m
each) and their size was measured by two operators; the
average of each parameter was then calculated.
2.4. RNA Isolation. Total RNA (including miRNAs) was
purified from SAT using the mirVana miRNA isolation kit
(Ambion, Austin, TX, USA), and its concentration was eval-
uated by NanoDrop ND-1000 UV-Vis spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA).
2.5. miRNAs Expression Profile. TaqMan low density arrays
HumanMicroRNA Panel v1.0 (Applied Biosystems Inc., Fos-
ter City, CA, USA), containing 377 preloaded humanmiRNA
targets and the endogenous control RNU48, were used
according to the manufacturer’s instructions. RT-PCR was
performed with 800 ng of cDNA and the 7900 HT real-time
PCR system (Applied Biosystems) as reported elsewhere [7].
miRNA expression was normalized to RNU48 and quantified
using the RQ Manager 1.2 software (Applied Biosystems)
with the following formula: RQ = 2−ΔΔCt, where ΔΔCt =
(Ctobese[miRNA] −Ctobese[RNU48]) − (Ctcalibrator[miRNA] −
Ctcalibrator[RNU48]). miRNAswhosemean baseline RQ levels
were <0.5 (downexpressed) or >2.0 (upexpressed) in all
obese patients versus controls were considered differently
expressed. We compared the expression of these differently
expressed miRNAs with those previously reported in the
SAT of other obese cohorts [6, 8–14]. Only miRNAs whose
expression trend was confirmed were selected for evaluation
after LAGB.
The levels of miR-370 and miR-487a (upexpressed)
and miR-519d (downexpressed) were validated by TaqMan
miRNA assays (Applied Biosystems) in accordance with the
manufacturer’s instructions on the 7900 HT real-time PCR
system (Applied Biosystems).
2.6. PPAR-AlphaWestern Blot. Total proteins were extracted,
quantified, and separated by 15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Western blot analyses
of PPAR-𝛼 (dilution 1 : 400) and actin (dilution 1 : 1000)
proteins were performed with antibodies from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) [6].
2.7. Bioinformatics. The MiRTarBase, STRING, and KEGG
databases were used to select the experimentally validated
miRNA/target gene interaction, to explore protein-protein
interactions and to identify the pathways significantly (𝑝 <
0.001) deregulated, respectively.
2.8. Statistics. Biochemical and clinical data are expressed as
mean and standard error of themean (SEM),whereasmiRNA
expression data are reported as log10 mean RQ and SEM.
The Wilcoxon test was used to compare data obtained at T0
and T1. Differences were considered statistically significant at
𝑝 < 0.05. Statistical analyses were carried out with the PASW
Statistics (Ver.18; SPSS Inc. Headquarters, Chicago, Ill. USA).
3. Results
Leptin levels and the L/A ratio were lower, whereas
adiponectin levels were higher, although not significantly,
at T1 versus T0 (Table 1). Furthermore, the number of SAT
adipocytes was higher and their diameter lower (𝑝 < 0.05) at
T1 versus T0 (Table 1) in all three obese patients. Overall, 68%
(257/377) ofmiRNAswere expressed at T0 in SAT fromobese
and control subjects. Most of these miRNAs (199/257) were
not differentially expressed between obese and lean subjects
and were not further investigated, whereas 58 miRNAs were
upexpressed (74%, 43/58) or downexpressed (26%, 15/58) in
obese versus controls (Table 2).
Table 2 also shows the 31/58 miRNAs (25 upexpressed
and 6 downexpressed) previously reported to have a similar
obese-associated trend in other cohorts [6, 8–14]. Six of these
31 miRNAs showed post-LAGB changes: miR-519d, miR-
299-5p, miR-212, and miR-671-3p were downexpressed at T1
versus T0, andmiR-370 andmiR-487awere upexpressed at T1
versus T0 (Figure 1(a)). Single RT-PCR assay confirmedmiR-
370, miR-487a, and miR-519d post-LAGB expression (mean
RQvalues: 3.54, 3.79, and 0.65, resp., at T1 versusT0).Notably,
at Western blot analysis, the expression of protein PPAR-𝛼,
whose mRNA is targeted by miR-519d [6], was significantly
higher (𝑝 < 0.05) at T1 versus T0 (mean OD/SD: 1.84/0.3
versus 0.72/0.4, resp.) (Figure 1(b)).
Bioinformatics predicted that, by targeting several genes,
these six miRNAs significantly (𝑝 < 0.001) regulated inter-
related pathways associated with the cytoskeleton, inflam-
mation, and metabolism, that is, FoxO, cell cycle, toll-like
receptor,MAPK, AMPK, p53, PI3K-Akt, adipocytokine, tight
and adherens junctions, focal adhesion, mTOR, PPAR, TGF-
beta, and apoptosis (Table 3 and Figure 2).
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Table 1: Clinical and biochemical parameters measured in three obese females (OB) before (T0) and three years after LAGB (T1).∗
OB1 OB2 OB3
T0 T1 T0 T1 T0 T1
BMI (kg/m2)∗∗ 41.5 28.4 37.2 28.1 50.0 39.5
EWL (%) 71.4 66.7 36.2
Na+ (mmol/L) 138.0 143.0 142.0 139.0 143.0 142.0
K+ (mmol/L) 4.0 4.3 4.3 4.8 4.7 4.7
Ca++ (mg/dL) 10.1 9.3 9.5 10.8 9.2 9.9
Phosphorus (mg/dL) 3.4 3.1 3.7 3.4 2.9 3.6
Fe (𝜇g/dL) 90.0 49.0 145.0 72.0 47.0 85.0
Glucose (mmol/L) 5.7 5.8 4.6 4.8 5.0 4.9
Insulin (mU/L) 6.1 11.3 12.9 3.5 51.9 11.2
HOMA 2.9 1.6 2.6 0.7 11.5 2.4
Cholesterol (mmol/L) 5.0 4.9 5.0 4.8 4.1 4.8
Triglycerides (mmol/L) 0.9 0.8 1.0 0.5 0.8 1.0
AST (U/L) 17.0 15.0 24.0 13.0 24.0 26.0
ALT (U/L) 20.3 11.0 24.0 26.0 23.0 26.0
ALP (U/L) 90.0 74.0 64.0 58.0 112.0 110.0
GGT (U/L) 16.7 11.0 20.0 12.0 15.0 12.0
LDH (U/L) 307.0 375.0 374.0 102.0 335.0 336.0
CHE (U/L) 10037.3 6497.0 11312.0 8383.7 8721.0 8855.0
CK (U/L) 100.0 51.0 128.0 97.7 61.0 54.0
AMS (U/L) 53.0 53.0 39.0 45.0 56.0 78.0
Urea (mmol/L) 0.4 0.5 0.5 0.5 0.7 0.5
Creatinine (𝜇mol/L) 53.0 53.0 61.9 53.0 61.9 70.7
UA (mmol/L) 0.3 0.2 0.3 0.2 0.3 0.3
T-bil (𝜇mol/L) 9.7 7.7 18.1 6.8 6.8 12.1
TP (g/dL) 7.8 7.5 7.7 6.4 8.0 8.3
Albumin (g/dL) 4.2 4.4 4.8 4.5 4.0 4.6
Adiponectin (𝜇g/mL) 9.4 19.5 7.7 15.7 9.9 17.1
Leptin (ng/mL) 43.1 8.5 22.4 12.4 32.2 16.6
Leptin/adiponectin ratio 4.6 0.4 2.9 0.8 3.2 1.0
Adipocyte number∗∗ 31 55 35 48 31 46
Adipocyte diameter (𝜇m)∗∗ 14 8 13 9 14 10
∗Data from [3]. ∗∗Statistically significant differences at T0 versus T1 at Wilcoxon’s test; 𝑝 < 0.01.
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AMS: amylase; AST: aspartate aminotransferase; BMI: body mass index; CHE: cholinesterase;
CK: creatine kinase; EWL: excess weight loss; GGT: 𝛾-glutamyl transferase; HOMA: homeostasis model assessment; LDH: lactate dehydrogenase; T-bil: total
bilirubin; TP: total proteins; UA: uric acid.
4. Discussion
In three obese patients, we identified 6 miRNAs whose
expression levels were either lower (miR-519d, miR-212, miR-
299-5p, and -miR-671-3p) or higher (miR-370 and miRNA-
487a) after LAGB. These miRNAs were predicted to regulate
pathways involved in obesity or in obesity-related cellu-
lar dysfunctions, the most significant being adipocytokine
and PPAR signaling, some interrelated metabolic pathways
(FoxO, cell cycle, MAPK, AMPK, p53, PI3K-Akt, TGF-
beta signaling, and apoptosis), the cytoskeleton, and cell-cell
adhesion (focal adhesion and tight and adherens junctions).
We previously found higher miR-519d expression in SAT
from another group of obese patients versus lean subjects
and demonstrated that it targeted PPAR-𝛼 mRNA, thereby
reducing the level of this protein in SAT and causing
lipid accumulation during adipocyte differentiation [6]. Data
obtained in PPAR-𝛼-null mice showed that this protein is
involved in lipid homeostasis [15]. Thus, our finding of
lower miR-519d levels and higher PPAR-𝛼 protein expression
in SAT after LAGB, together with the significantly (𝑝 <
0.05) smaller diameter and higher number of adipocytes
at T1 versus T0, suggests that surgery might improve lipid
metabolism and adipose tissue functionality also via a miR-
519d-mediated mechanism. Accordingly, PPAR-𝛼 activation
was reported to induce removal of intracellular lipids through
fatty acid oxidation [15] and to be a part of a regulatory
loop that controls the metabolic response of adipose tissue
to nutrients and other signals [15]. Furthermore, PPAR-𝛼 is
also a nutritional sensor adapting metabolic homeostasis to
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Table 2: Differently expressed miRNAs at T0 in obese patients
versus normal-weight subjects.
Upexpressed miRNAs Downexpressed miRNAs
hsa-let-7a hsa-miR-18b
hsa-let-7d hsa-miR-107
hsa-let-7e hsa-miR-200a
hsa-let-7f hsa-miR-200c
hsa-miR-10a hsa-miR-205
hsa-miR-21 hsa-miR-331-5p
hsa-miR-27b hsa-miR-342-5p
hsa-miR-29c hsa-miR-370
hsa-miR-34a hsa-miR-382
hsa-miR-92a hsa-miR-429
hsa-miR-95 hsa-miR-487a
hsa-miR-99b hsa-miR-496
hsa-miR-100 hsa-miR-520a-3p
hsa-miR-125b hsa-miR-548c-5p
hsa-miR-128 hsa-miR-615-5p
hsa-miR-130a
hsa-miR-130b
hsa-miR-145
hsa-miR-146b-5p
hsa-miR-190
hsa-miR-195
hsa-miR-199b-5p
hsa-miR-204
hsa-miR-212
hsa-miR-221
hsa-miR-224
hsa-miR-296-5p
hsa-miR-299-5p
hsa-miR-323-3p
hsa-miR-328
hsa-miR-339-5p
hsa-miR-362-3p
hsa-miR-365
hsa-miR-494
hsa-miR-519d
hsa-miR-520g
hsa-miR-532-3p
hsa-miR-652
hsa-miR-655
hsa-miR-671-3p
hsa-miR-708
hsa-miR-744
hsa-miR-758
Italic type indicates miRNAs whose expression trend was similar to those of
previous studies [6, 8–14]. These miRNAs were investigated after LAGB.
energy deprivation; it exerts an anti-inflammatory function
and controls also some aspects of the glucose and lipid
metabolism in several tissues included the adipose one [16].
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Figure 1: Six miRNAs whose expression changed in subcuta-
neous adipose tissue (SAT) three years after LAGB (T1) and
Western blot evaluation of protein PPAR𝛼, which is targeted
by miR-519d. (a) Expression levels of 4 downexpressed (miR-
212, miR-299-5p, miR-519d, and miR-671-3p) and 2 upexpressed
miRNAs (miR-370 and miR-487a) after LAGB (T1 versus T0).
MiRNA expression levels are shown as mean log10RQ (the
miRNA expression values were first normalized to RNU48,
after which the relative quantification was calculated as RQ =
2−ΔΔCt, where ΔΔCt = [Ct obese(miRNA) − Ct obese(RNU48)] –
[Ct calibrator(miRNA)–Ct calibrator(RNU48)]. (b) Western blot
evaluation of protein PPAR-𝛼 from SAT of 3 obese patients before
(T0) and three years (T1) after LAGB.
The decrease of miR-212, miR-299-5p, and miR-671-3p
levels that we found at T1 versus T0 was predicted to be
associated with reduced SAT inflammation. This is in line
with the findings that (i) miR-212 is directly involved in
inflammation and immune processes [17] and (ii) miR-299-
5p, by upregulating its target gene SPP1, could promote endo-
cytosis of cell debris and indirectly reduce inflammation [18].
Lastly, an earlier study showed that miR-671-3p expression
was lower in visceral fat from obese patients with nonalco-
holic steatohepatitis versus obese patients with nonalcoholic
fatty liver disease [19] and was related to decreased liver
inflammation.
Concerning miR-212, it was demonstrated to be upex-
pressed in high fat fed mice and its levels measured in
liver were downregulated by physical activity [20]. miR-
212 positively regulated fatty acids biosynthesis and hepatic
storage by acting on fibroblast growth factor 21 (FGF-21)
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Table 3: Metabolic pathways predicted to change by our miRNAs after LAGB.Themost significant pathways (𝑝 < 0.005) predicted by KEGG
to contain genes targeted by the 6 miRNAs whose expression changed three years after LAGB.
KEGG pathways
Pathway description (ID) FDR miRNAs
FoxO signaling pathway (4068)
AKT3, CCNB1, CDKN1A, FOXO1, PTEN, SOD2,
TGFBR2
1.05𝑒 − 07
miR-519d, miR-212,
miR-299-5p, miR-370
Cell cycle (4110)
CCNA2, CCNB1, CDKN1A, MYC, RB1 4.03𝑒 − 05
miR-519d, miR-299-5p,
miR-212
Toll-like receptor signaling pathway (4620)
AKT3, IRAK4, MAP3K8, SPP1 0.000363
miR-519d, miR-299-5p,
miR-212, miR-370
MAPK signaling pathway (4010)
AKT3, MAP3K8, MYC, NF1, TGFBR2 0.000567
miR-519d, miR-212,
miR-370
AMPK signaling pathway (4152)
AKT3, CCNA2, CPT1A, FOXO1 0.000567
miR-519d, miR-212,
miR-370
p53 signaling pathway (4115)
CCNB1, CDKN1A, PTEN 0.00167
miR-519d, miR-299-5p,
miR-212
PI3K-Akt signaling pathway (4151)
AKT3, CDKN1A, MYC, PTEN, SPP1 0.00167
miR-519d, miR-299-5p,
miR-212
Adipocytokine signaling pathway (4920)
AKT3, CPT1A, PPARA 0.00167 miR-519d, miR-370
Tight junction (4530)
AKT3, PTEN, TJP1 0.00821 miR-519d, miR-212
Focal adhesion (4510)
AKT3, PTEN, SPP1 0.0259 miR-519d, miR-299-5p
mTOR signaling pathway (4150)
AKT3, PTEN 0.0269 miR-519d
PPAR signaling pathway (3320)
CPT1A, PPARA 0.0346 miR-370, miR-519d
Adherens junction (4520)
TGFBR2, TJP1 0.0356 miR-370, miR-212
TGF-beta signaling pathway (4350)
MYC, TGFBR2 0.0418 miR-212, miR-370
Apoptosis (4210)
AKT3, IRAK4 0.0483 miR-519d, miR-212
Figure 2: Metabolic pathways predicted to change by our miRNAs
after LAGB. Network identified by STRING showing a close inter-
action among the proteins regulated by the subset of 6 miRNAs.The
above 6 miRNAs also targeted the pathways of several proteins in
cancer and infection diseases (data not reported).
[20]. Interestingly, FGF-21 is a target gene of PPAR-𝛼 and is
involved in cellular response to oxidative stress [21].
Consequently, the reduced SAT expression of both miR-
212 and -519d, that we observed in our obese patients after
LAGB, could exert a role in reducing oxidative stress and
inflammation by acting on the PPAR-𝛼-FGF-21 axis. In agree-
ment with this hypothesis, we previously reported a reduced
SAT inflammation after LAGB in a larger cohort compared to
the present [3] and here we suggest that this effect could be,
in part, caused by a miRNA-mediated mechanism.
Finally, although miR-370 and 487a, which were upex-
pressed after LAGB, were predicted to regulate the expression
of genes belonging to several metabolic pathways, their con-
tribution to surgery metabolic improvement, if any, remains
to be established.
5. Conclusions
In conclusion, although our data were obtained in only
three patients (mainly because patients were unwilling to
6 Journal of Obesity
undergo a post-LAGB biopsy), we show that the miRNA
profile changes after LAGB. This finding suggests that this
epigenetic mechanism, by regulating the expression of genes
involved in inflammation and lipidmetabolism, could concur
to improve SAT functionality in postoperative obese patients.
Conflicts of Interest
The authors declare no conflicts of interest regarding the
publication of this paper.
Authors’ Contributions
Carmela Nardelli and Laura Iaffaldano contributed equally to
the paper.
Acknowledgments
The authors thank Jean Ann Gilder (Scientific Commu-
nication SRL, Naples, Italy) for revising and editing the
manuscript and Vittorio Lucignano, CEINGE-Biotecnologie
Avanzate, for technical assistance related to graphics. They
also acknowledge grants from CEINGE Regione Campania
(DGRC 1901/2009), IRCCS SDN, Ministry of Health, POR
Campania FSE 2007-2013-CUP B25B09000050007, Project
CREME, and Project PON02 00619 3461281.
References
[1] N. Esser, S. Legrand-Poels, J. Piette, A. J. Scheen, and N. Paquot,
“Inflammation as a link between obesity, metabolic syndrome
and type 2 diabetes,”Diabetes Research andClinical Practice, vol.
105, no. 2, pp. 141–150, 2014.
[2] F. Favretti, G. Segato, D. Ashton et al., “Laparoscopic adjustable
gastric banding in 1,791 consecutive obese patients: 12-year
results,” Obesity Surgery, vol. 17, no. 2, pp. 168–175, 2007.
[3] L. Iaffaldano, C. Nardelli, V. Pilone et al., “Laparoscopic
adjustable gastric banding reduces subcutaneous adipose tissue
and blood inflammation in nondiabetic morbidly obese indi-
viduals,” Obesity Surgery, vol. 24, no. 12, pp. 2161–2168, 2014.
[4] W. T. Garvey, J. I. Mechanick, E. M. Brett et al., “American
Association of Clinical Endocrinologists and American College
of Endocrinology clinical practice guidelines for comprehensive
medical care of patients with obesity—executive summary,”
Endocrine Practice, vol. 22, supplement 3, pp. 1–203, 2016.
[5] S. Vienberg, J. Geiger, S. Madsen, and L. T. Dalgaard, “MicroR-
NAs in metabolism,” Acta Physiologica, 2016.
[6] R.Martinelli, C.Nardelli, V. Pilone et al., “MiR-519d overexpres-
sion Is associated with human obesity,” Obesity, vol. 18, no. 11,
pp. 2170–2176, 2010.
[7] V. Capobianco, C. Nardelli, M. Ferrigno et al., “MiRNA and
protein expression profiles of visceral adipose tissue reveal
miR-141/YWHAG and miR-520e/RAB11A as two potential
miRNA/protein target pairs associated with severe obesity,”
Journal of Proteome Research, vol. 11, no. 6, pp. 3358–3369, 2012.
[8] Y. Peng, H. Xiang, C. Chen et al., “MiR-224 impairs adipocyte
early differentiation and regulates fatty acid metabolism,” Inter-
national Journal of Biochemistry and Cell Biology, vol. 45, no. 8,
pp. 1585–1593, 2013.
[9] Y. J. Kim, S. H. Hwang, H. H. Cho, K. K. Shin, Y. C. Bae, and
J. S. Jung, “MicroRNA 21 regulates the proliferation of human
adipose tissue-derived mesenchymal stem cells and high-fat
diet-induced obesity alters microRNA 21 expression in white
adipose tissues,” Journal of Cellular Physiology, vol. 227, no. 1,
pp. 183–193, 2012.
[10] N. Arias, L. Aguirre, A. Ferna´ndez-Quintela et al., “MicroRNAs
involved in the browning process of adipocytes,” Journal of
Physiology and Biochemistry, vol. 72, no. 3, pp. 509–521, 2016.
[11] T. Fu, S. Seok, S. Choi et al., “MicroRNA 34a inhibits beige and
brown fat formation in obesity in part by suppressing adipocyte
fibroblast growth factor 21 signaling and SIRT1 function,”
Molecular and Cellular Biology, vol. 34, no. 22, pp. 4130–4142,
2014.
[12] J. Yu, Y. Chen, L. Qin et al., “Effect of miR-205 on 3T3-
L1 preadipocyte differentiation through targeting to glycogen
synthase kinase 3 beta,” Biotechnology Letters, vol. 36, no. 6, pp.
1233–1243, 2014.
[13] P. Arner and A. Kulyte´, “MicroRNA regulatory networks in
human adipose tissue and obesity,” Nature Reviews Endocrinol-
ogy, vol. 11, no. 5, pp. 276–288, 2015.
[14] A. Masotti, A. Baldassarre, M. Fabrizi et al., “Oral glucose
tolerance test unravels circulating miRNAs associated with
insulin resistance in obese preschoolers,”PediatricObesity, 2016.
[15] M. C. Sugden, P. W. Caton, and M. J. Holness, “PPAR control:
it’s SIRTainly as easy as PGC,” Journal of Endocrinology, vol. 204,
no. 2, pp. 93–104, 2010.
[16] D. Portius, C. Sobolewski, andM. Foti, “MicroRNAs-dependent
regulation of PPARs in metabolic diseases and cancers,” PPAR
Research, vol. 2017, Article ID 7058424, 19 pages, 2017.
[17] A. Wanet, A. Tacheny, T. Arnould, and P. Renard, “MiR-212/132
expression and functions: within and beyond the neuronal
compartment,” Nucleic Acids Research, vol. 40, no. 11, pp. 4742–
4753, 2012.
[18] K. Schuch, B. Wanko, K. Ambroz et al., “Osteopontin affects
macrophage polarization promoting endocytic but not inflam-
matory properties,” Obesity, vol. 24, no. 7, pp. 1489–1498, 2016.
[19] M. Estep, D. Armistead, N. Hossain et al., “Differential expres-
sion of miRNAs in the visceral adipose tissue of patients with
non-alcoholic fatty liver disease,”Alimentary Pharmacology and
Therapeutics, vol. 32, no. 3, pp. 487–497, 2010.
[20] J. Xiao, Y. Bei, J. Liu et al., “miR-212 downregulation contributes
to the protective effect of exercise against non-alcoholic fatty
liver via targeting FGF-21,” Journal of Cellular and Molecular
Medicine, vol. 20, no. 2, pp. 204–216, 2016.
[21] M. A´. Go´mez-Sa´mano, M. Grajales-Go´mez, J. M. Zuarth-
Va´zquez et al., “Fibroblast growth factor 21 and its novel
associationwith oxidative stress,”Redox Biology, vol. 11, pp. 335–
341, 2017.
